Published in Ann Neurol on January 01, 1998
A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 2.03
Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol (2005) 1.50
Multiple sclerosis review. P T (2012) 1.34
Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol (2009) 1.18
Sex differences in autoimmune diseases. Biol Sex Differ (2011) 1.16
Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol (2007) 1.08
Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry (2001) 1.06
Drug treatment of multiple sclerosis. BMJ (2000) 1.02
Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry (2000) 1.02
Immunomodulatory treatment strategies in multiple sclerosis. J Neurol (2008) 0.99
One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 0.99
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol (2005) 0.96
Current and future therapies for multiple sclerosis. Scientifica (Cairo) (2013) 0.92
Treatment of multiple sclerosis: role of natalizumab. Neurol Sci (2009) 0.88
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol (2007) 0.87
Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics (2011) 0.85
Complexity of the microglial activation pathways that drive innate host responses during lethal alphavirus encephalitis in mice. ASN Neuro (2012) 0.84
Drug treatment of multiple sclerosis West J Med (2000) 0.84
The importance of maintaining effective therapy in multiple sclerosis. J Neurol (2005) 0.82
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr (2012) 0.82
Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol (2003) 0.81
Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2008) 0.80
Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? BMC Neurol (2011) 0.78
Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Mult Scler Int (2013) 0.77
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. J Neural Transm (Vienna) (2012) 0.76
Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response. J Neurol (2004) 0.76
MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort. BMC Neurol (2016) 0.75
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients. J Cent Nerv Syst Dis (2011) 0.75
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther (2010) 0.75
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther (2013) 0.75
Imaging and multiple sclerosis. Ann Neurol (1998) 0.75
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. BMC Med Imaging (2016) 0.75
Approved Beta interferons in relapsing-remitting multiple sclerosis: is there an odd one out? J Cent Nerv Syst Dis (2012) 0.75
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag (2015) 0.75
A pilot study to improve adherence among MS patients who discontinue treatment against medical advice. J Behav Med (2015) 0.75
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. Eur J Clin Pharmacol (2016) 0.75
Is multiple sclerosis a disease that requires frequent beta interferon dosing? J Neurol (2004) 0.75
Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis. AJNR Am J Neuroradiol (2017) 0.75
Automated microbiological detection/identification system. J Clin Microbiol (1977) 16.88
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 1. Epidemiologic results. Ann Intern Med (1983) 6.67
The visible human male: a technical report. J Am Med Inform Assoc (1996) 5.05
Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev (1995) 4.89
The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil (1987) 4.86
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
The surveillance of infectious diseases. JAMA (1983) 4.41
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Neurotrophins are required for nerve growth during development. Nat Neurosci (2001) 3.96
An evaluation of influenza mortality surveillance, 1962-1979. I. Time series forecasts of expected pneumonia and influenza deaths. Am J Epidemiol (1981) 3.88
Cross sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int (1993) 3.86
Interrater reliability of the 7-level functional independence measure (FIM) Scand J Rehabil Med (1994) 3.86
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
Morbidity and mortality associated with the July 1980 heat wave in St Louis and Kansas City, Mo. JAMA (1982) 3.69
The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehabil (1996) 3.41
The structure and stability of the Functional Independence Measure. Arch Phys Med Rehabil (1994) 3.30
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Maintenance of broad-host-range incompatibility group P and group Q plasmids and transposition of Tn5 in Bartonella henselae following conjugal plasmid transfer from Escherichia coli. J Bacteriol (1997) 3.18
Risk factors for heatstroke. A case-control study. JAMA (1982) 3.15
Scaling of the distribution of price fluctuations of individual companies. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1999) 3.12
Scaling of the distribution of fluctuations of financial market indices. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1999) 3.12
Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol (1991) 3.10
Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med (1972) 3.09
Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and PtdIns-3,4,5-P3. J Biol Chem (1994) 3.08
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol (1995) 3.06
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
Validation of questionnaire and bronchial hyperresponsiveness against respiratory physician assessment in the diagnosis of asthma. Int J Epidemiol (1996) 2.91
The Functional Independence Measure: tests of scaling assumptions, structure, and reliability across 20 diverse impairment categories. Arch Phys Med Rehabil (1996) 2.86
Light and electron microscopic observations on Rosenthal fibers in Alexander's disease and in multiple sclerosis. J Neuropathol Exp Neurol (1970) 2.85
Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res (1994) 2.82
Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr (1999) 2.79
A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature (1997) 2.78
Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil (1979) 2.64
Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study. Neurology (1996) 2.55
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature (1988) 2.47
Statistical properties of the volatility of price fluctuations. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1999) 2.46
Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci U S A (2000) 2.44
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science (1989) 2.40
Cre recombinase expression in cerebellar Purkinje cells. Genesis (2001) 2.35
An evaluation of influenza mortality surveillance, 1962-1979. II. Percentage of pneumonia and influenza deaths as an indicator of influenza activity. Am J Epidemiol (1981) 2.32
Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development (1997) 2.32
Complete mitochondrial genomes of ancient canids suggest a European origin of domestic dogs. Science (2013) 2.31
Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. J Cell Biol (1999) 2.31
Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950-69. J Natl Cancer Inst (1977) 2.28
A controlled trial of disease surveillance strategies. Am J Prev Med (1988) 2.23
Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol (1984) 2.21
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16
Outcome of comprehensive medical rehabilitation: measurement by PULSES profile and the Barthel Index. Arch Phys Med Rehabil (1979) 2.14
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
The Visible Human data set: an image resource for anatomical visualization. Medinfo (1995) 2.01
Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci U S A (2004) 1.98
Aging and matrix microdamage accumulation in human compact bone. Bone (1995) 1.98
Ataxia and altered dendritic calcium signaling in mice carrying a targeted null mutation of the calbindin D28k gene. Proc Natl Acad Sci U S A (1997) 1.96
Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Arch Fam Med (1999) 1.94
Mortality during influenza epidemics in the United States, 1967-1978. Am J Public Health (1982) 1.93
Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol (1990) 1.90
Etiology of progressive multifocal leukoencephalopathy. Identification of papovavirus. N Engl J Med (1973) 1.90
Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci (2001) 1.89
NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology (2010) 1.88
Transfer and expression of the herbicide-degrading plasmid pJP4 in aerobic autotrophic bacteria. Arch Microbiol (1983) 1.87
Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation (1995) 1.86
A case-mix classification system for medical rehabilitation. Med Care (1994) 1.84
Viral infections and demyelinating diseases. N Engl J Med (1973) 1.84
A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics (1998) 1.84
Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest (1997) 1.83
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
An analytic model for the optical properties of gold. J Chem Phys (2006) 1.80
Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int (2006) 1.79
Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78
Glutamic acid: selective depletion by viral induced granule cell loss in hamster cerebellum. Brain Res (1974) 1.77
Functional status measures in a comprehensive stroke care program. Arch Phys Med Rehabil (1977) 1.76